AIM ImmunoTech Inc. plans to regain compliance with NYSE equity requirements by June 2026, focusing on oncology and antiviral advancements. The company is under scrutiny from the NYSE American for ...
AIM ImmunoTech Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
AIM ImmunoTech Inc. announced that it has received a notice from the NYSE American indicating that it is not in compliance with certain continued listing standards regarding stockholders' equity due ...
OCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (AIM) (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a ...
Today marks a pivotal moment in our company’s history as Power Probe, a business that started life in California back in 1992, will float on the London Stock Exchange’s AIM market. We’re headquartered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback